Amgen – Amgen : Sotorasib Shows Positive Responses in Phase Two Study
By Adriano Marchese
Amgen Inc. said Thursday its investigational drug, Sotorasib, has shown rapid, deep and durable response in a Phase 2 study.
The biotechnology company said 37.1% of patients with advanced non-small cell lung cancer responded to the treatment, with a median duration of response of ten months. Meanwhile, Median tumor shrinkage among all responders was 60%.
“We are extremely pleased that Sotorasib has successfully demonstrated rapid, deep and durable responses in this registrational Phase 2 study that was conducted in record time,” Executive Vice President of Research and Development David Reese said.
Write to Adriano Marchese at email@example.com
(END) Dow Jones Newswires